Retatrutide clinical trials: what does the evidence show?

Why this page is about trials, not claims

Retatrutide is an investigational triple agonist that activates the GLP-1, GIP and glucagon receptors. It has drawn attention because the body-weight reductions reported in human research — first in phase 2, then in the phase 3 TRIUMPH programme — were larger than those previously reported for the dual and single agonists already on the market.

That attention has run far ahead of the evidence base. Most of what circulates about retatrutide online is either extrapolated from earlier incretin drugs or repeated from sellers of research-grade material, neither of which is clinical evidence.

This guide sticks to what human studies have reported and what they have not yet established. For the compound overview — structure, mechanism, half-life and regulatory status — see the retatrutide peptide profile instead.

What retatrutide is, briefly

Retatrutide (development code LY3437943) is a synthetic peptide engineered to act on three metabolic receptors at once rather than one or two. The rationale is that GLP-1 and GIP activity reduce appetite and improve insulin response, while glucagon-receptor activity adds an energy-expenditure component.

It is not an approved medicine in any jurisdiction. Everything below comes from the investigational research programme, not from post-approval clinical use.

How a compound like this gets studied

Drug development moves through defined tiers, and each tier answers a narrower question than the marketing around it implies. Phase 1 asks whether a dose is tolerated. Phase 2 asks whether an effect exists and at what dose. Phase 3 asks whether that effect holds in a large, diverse population over a longer period, against a comparator, with enough participants to detect uncommon harms.

Retatrutide's evidence base now spans both tiers. Phase 1 and two phase 2 dose-ranging trials established that an effect exists and how it scales with dose; the phase 3 TRIUMPH programme has since reported much larger and longer trials. Several of those phase 3 results were announced during 2026 as company-reported topline results rather than full peer-reviewed publications, which changes how much weight they carry but not the direction of the evidence.

• Preclinical — receptor pharmacology and animal metabolic models; establishes plausibility only
• Phase 1 — small, short, focused on safety, tolerability and pharmacokinetics
• Phase 2 — dose-ranging; the first tier that gives a usable read on effect size
• Phase 3 — large randomised trials designed to confirm efficacy and characterise safety
• Regulatory review and post-marketing surveillance — where rare harms usually surface

The earlier evidence: phase 1 and phase 2

Phase 1 work established tolerability, pharmacokinetics and a workable weekly dosing schedule in small numbers of participants. It says nothing about efficacy.

Two randomised, double-blind, placebo-controlled phase 2 trials followed, both fully published and peer-reviewed. One enrolled 338 adults with obesity and ran for 48 weeks; the other enrolled adults with type 2 diabetes and ran for 36 weeks.^[1][2] Both tested ascending weekly doses against placebo, with escalation schedules designed to limit gastrointestinal intolerance.

The obesity trial measured percentage change in body weight as its primary endpoint. The diabetes trial measured change in HbA1c, with body weight among the secondary endpoints. Both recorded adverse events, discontinuations and standard laboratory and cardiovascular safety measures.

These were dose-finding studies, not confirmatory ones. They were designed to establish whether an effect exists and how it scales with dose — not to prove long-term benefit, and not to detect uncommon harms. That is the job phase 3 exists to do.

• Design — randomised, double-blind, placebo-controlled, multiple dose arms
• Populations — adults with obesity in one trial; adults with type 2 diabetes in the other
• Duration — under a year in both cases
• Primary endpoints — body-weight change, and glycaemic control respectively
• Question answered — does an effect exist, and is it dose-related
• Question left to phase 3 — confirmation in larger populations, longer exposure, and uncommon harms

The phase 3 TRIUMPH programme and the 2026 results

TRIUMPH is the phase 3 clinical programme for retatrutide, made up of separate large randomised trials in different populations, registered publicly before they reported.^[3][6] Results reported during 2026 substantially expand the human record beyond the earlier phase 2 picture, and most were first communicated as company-announced topline results, with full peer-reviewed trial reports and regulatory review still to follow.

TRIUMPH-1 studied adults with obesity over 80 weeks. The reported mean body-weight reductions were approximately 19.0% at 4 mg, 25.9% at 9 mg and 28.3% at 12 mg, against approximately 2.2% with placebo. In the reported 12 mg group, 45.3% of participants achieved at least 30% body-weight loss.^[4] As with any trial, those are group means in a population selected against entry criteria, receiving structured support, monitoring and a defined escalation schedule.

TRIUMPH-2 studied adults with obesity or overweight and type 2 diabetes over 80 weeks. Reported mean weight reductions were 12.7% at 4 mg, 19.1% at 9 mg and 20.8% at 12 mg, versus 4.0% with placebo, with reported A1C reductions of roughly 1.4–1.6% across the retatrutide groups compared with 0.2% on placebo.^[5][6] Weight loss is consistently smaller in type 2 diabetes populations across this drug class, which is why the two trials are not directly interchangeable.

TRIUMPH-3 studied adults with severe obesity and established cardiovascular disease over 80 weeks, with reported mean weight reductions of 21.6% at 9 mg and 22.6% at 12 mg versus 3.2% with placebo. It also reported cardiovascular-event analyses, and those need reading carefully rather than as a headline.

The reported hazard ratio for a five-component MACE composite was 0.82 (95% CI 0.55–1.22), and for the three-component MACE composite 1.12 (95% CI 0.64–1.96). Both confidence intervals cross 1. That means these analyses do not establish a reduction in cardiovascular events; the trial was not a dedicated cardiovascular-outcome trial, and its event numbers were not sufficient to settle the question either way.

TRIUMPH-4, in adults with obesity and knee osteoarthritis, was reported earlier, with up to approximately 28.7% mean weight loss at 68 weeks in the 12 mg group alongside reported improvements in osteoarthritis pain and function outcomes. Osteoarthritis-pain and sleep-apnoea findings from the programme were also reported by the sponsor in June 2026.^[5]

• TRIUMPH-1 — obesity, 80 weeks, up to approximately 28.3% mean weight reduction at 12 mg versus 2.2% placebo
• TRIUMPH-2 — obesity or overweight with type 2 diabetes, 80 weeks, up to 20.8% weight reduction and A1C reductions of about 1.4–1.6%
• TRIUMPH-3 — severe obesity with established cardiovascular disease, 80 weeks, up to 22.6% weight reduction; cardiovascular-event analyses inconclusive
• TRIUMPH-4 — obesity with knee osteoarthritis, 68 weeks, up to approximately 28.7% weight loss with reported pain and function improvements
• Status — largely company-reported topline results in 2026, pending full publication and regulatory review^[4][5]

What the trials reported for body weight

Across both tiers the pattern is the same: mean body-weight reduction rises with dose and is far greater than placebo. In the 48-week phase 2 obesity trial the weight curves had not clearly flattened by the end of treatment; the 80-week phase 3 TRIUMPH-1 result, at approximately 28.3% mean reduction at 12 mg, is consistent with that trajectory continuing over a longer exposure.

Two cautions belong with those numbers. First, they are group means from trial populations selected against entry criteria; individual responses in any incretin trial vary widely, and a mean is not a promise. Second, participants received structured support, dose escalation and monitoring alongside the drug, which is not how research-grade material bought online is used.

The phase 3 results also make clear how much the population matters: the same doses produced roughly 28% mean loss in obesity without diabetes and roughly 21% in obesity with type 2 diabetes. What happens after treatment stops was not characterised by these trials.

What the trials reported for metabolic outcomes

In the phase 2 type 2 diabetes trial, retatrutide produced dose-dependent reductions in HbA1c relative to placebo alongside weight reduction. The reported phase 3 TRIUMPH-2 results point the same way at scale, with A1C reductions of roughly 1.4–1.6% across the retatrutide groups against 0.2% on placebo. Improvements in related measures such as lipids and blood pressure have been reported as secondary or exploratory findings.

Secondary and exploratory endpoints carry less weight than primary ones. They are not powered to be conclusive on their own, and a trial can show a real primary effect while a secondary signal turns out to be noise. Treat them as directions for further study, not as established outcomes.

Crucially, no trial has yet demonstrated that retatrutide reduces cardiovascular events or mortality. The TRIUMPH-3 cardiovascular analyses had confidence intervals crossing 1 in both directions, so they neither establish nor exclude a benefit. Improving a metabolic marker is a surrogate outcome; it makes benefit plausible without demonstrating it.

What the safety results show

The adverse-event profile reported in the phase 2 trials was dominated by gastrointestinal effects — nausea, vomiting, diarrhoea and constipation — consistent with the incretin class as a whole. These were mostly reported as mild to moderate, were more frequent at higher doses, and were more common during dose escalation than at maintenance.

Dose-dependent increases in heart rate were also observed, a finding that warrants attention in a compound intended for long-term metabolic use and one of the reasons longer trials matter. Discontinuation due to adverse events occurred and, as is typical, was more frequent in higher-dose arms than with placebo.

What phase 2 cannot do is characterise uncommon or delayed harms. Trials of this size and duration detect frequent, early adverse events well and rare or late ones poorly. Absence of a reported signal at this stage is not evidence that no such signal exists.

• Commonly reported — gastrointestinal effects, mostly mild to moderate and dose-related
• Physiological signals — dose-dependent heart-rate increases
• Discontinuation — occurred, more frequently in higher-dose arms
• Not characterised — rare events, delayed events, and multi-year exposure

The limitations that matter most

Phase 3 has answered a great deal that phase 2 could not: larger populations, 80 weeks of exposure, several distinct patient groups. The compound is no longer described fairly as a phase 2 story. But several important limitations remain, and the first is publication status — much of the 2026 phase 3 evidence has been communicated as company-reported topline results rather than full peer-reviewed trial reports, so the complete data, subgroup detail and independent scrutiny are still pending.

The second is duration and long-term safety. Obesity management is measured in years; the longest reported trials run 80 weeks. Uncommon and delayed adverse events require larger and longer exposure than any trial programme has yet accumulated, and durability of weight loss after discontinuation remains an open and clinically important question.

The third is the difference between surrogate markers and hard clinical outcomes. Weight and A1C are strong surrogates, but the TRIUMPH-3 cardiovascular analyses did not establish an event reduction. Positive trial results are also distinct from regulatory approval: retatrutide remains investigational and is not an approved medicine.

A fourth applies specifically to material bought outside a clinical setting: nothing about a trial result transfers to a vial whose identity, purity and content have not been verified. Trial evidence describes a characterised investigational drug product used under controlled conditions, not an unverified powder.

Better established versus still uncertain

Separating the two is the most useful thing a reader can take from the current evidence base.

• Better established — substantial, dose-dependent body-weight reduction in randomised placebo-controlled phase 2 and phase 3 trials
• Better established — the effect has been reproduced across several studied populations, including obesity, type 2 diabetes, established cardiovascular disease and knee osteoarthritis
• Better established — improvements in glycaemic control in populations with type 2 diabetes
• Better established — gastrointestinal adverse events are common, dose-related and escalation-related, and are the main tolerability issue
• Better established — phase 3 evidence is substantially stronger on efficacy than the earlier phase 2-only record
• Still uncertain — long-term safety over multiple years, including the significance of heart-rate changes
• Still uncertain — durability of weight loss after discontinuation
• Still uncertain — uncommon and rare adverse events
• Still uncertain — definitive cardiovascular outcome benefit; reported analyses had confidence intervals crossing 1
• Still uncertain — final regulatory conclusions; retatrutide remains investigational
• Still uncertain — how trial findings translate outside controlled clinical research, including unsupervised use of unregulated material

How to read new retatrutide claims

When a new figure circulates, three questions settle most of it. Was it a human study or an animal or modelling result? Was it randomised and controlled, or a single-arm observation? And was the number reported the primary endpoint the trial was designed to test, or a secondary finding lifted out of context?

The same distinction between mechanism and outcome that applies across the peptide field applies here, and the guide on how peptides work covers it in more depth. Triple-receptor pharmacology explains why researchers expected an effect; it does not by itself establish one.

For a like-for-like read against the compounds retatrutide is usually measured against, the retatrutide and tirzepatide comparison and the semaglutide and retatrutide comparison set the evidence bases side by side.

Bottom line

Retatrutide has been studied in humans, in randomised placebo-controlled trials, and the reported results are substantial rather than marginal. That much is not in dispute.

What has not happened yet is the multi-year, hard-endpoint, fully published evidence that separates a strong trial programme from an established treatment. Much of the 2026 phase 3 data is still company-reported topline rather than peer-reviewed, retatrutide remains investigational and unapproved, and the evidence base is now strong on effect size and still thin on everything that takes years to measure.

Sources & primary evidence

Numbered markers in the text above link to the entries below. Source types are labelled so primary human research, animal work, trial registrations and company-reported results stay distinguishable — see how PeptideIndex grades evidence.

1. [1] Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (Jastreboff et al.)

   New England Journal of Medicine · 2023 · Peer-reviewed phase 2 randomised trial

2. [2] Retatrutide for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled phase 2 trial (Rosenstock et al.)

   The Lancet · 2023 · Peer-reviewed phase 2 randomised trial

3. [3] TRIUMPH-1: retatrutide in participants who have obesity or overweight (NCT05929066)

   ClinicalTrials.gov · 2023–2026 · Phase 3 trial registration and record

4. [4] Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial

   Eli Lilly and Company (PR Newswire) · 2026 · Company-reported Phase 3 topline results; peer-reviewed publication pending

5. [5] Retatrutide improvements in weight, A1C, knee osteoarthritis pain and obstructive sleep apnoea (TRIUMPH-1 and TRANSCEND-T2D-1)

   Eli Lilly and Company (PR Newswire) · 2026 · Company-reported Phase 3 results; conference-presented, publication status varies by trial

6. [6] TRIUMPH-2: retatrutide in participants with type 2 diabetes who have obesity or overweight (NCT05929079)

   ClinicalTrials.gov · 2023–2026 · Phase 3 trial registration and record

Frequently asked questions

Has retatrutide been studied in humans?

Yes. Retatrutide has been evaluated in randomised, double-blind, placebo-controlled human trials, including phase 2 studies in obesity and type 2 diabetes and the larger phase 3 TRIUMPH programme, with several TRIUMPH results reported during 2026. It remains investigational and is not approved for medical use in any jurisdiction.

What do clinical trials show about retatrutide and weight loss?

Phase 3 results reported in 2026 go well beyond the earlier 48-week phase 2 trial. TRIUMPH-1 reported mean body-weight reductions at 80 weeks of about 19.0% at 4 mg, 25.9% at 9 mg and 28.3% at 12 mg versus about 2.2% with placebo, with 45.3% of the 12 mg group losing at least 30%. In obesity with type 2 diabetes, TRIUMPH-2 reported 12.7%, 19.1% and 20.8% versus 4.0% with placebo. These are group means from monitored trial populations, and several results are company-reported topline figures rather than full publications.

What do clinical trials show about retatrutide side effects?

Gastrointestinal adverse events — nausea, vomiting, diarrhoea and constipation — were the most commonly reported, mostly mild to moderate, more frequent at higher doses and during dose escalation. Dose-dependent increases in heart rate were also observed. Even phase 3 trials of this size and duration cannot characterise rare or delayed harms.

Is the clinical evidence for retatrutide conclusive?

The evidence is substantially stronger following the phase 3 TRIUMPH results, which tested larger populations over 80 weeks, but it is not equivalent to a fully established, approved therapy with long-term post-marketing data. Much of the 2026 evidence is company-reported topline rather than peer-reviewed, cardiovascular-event analyses were inconclusive with confidence intervals crossing 1, and long-term safety and durability after discontinuation remain open.

How does the retatrutide evidence base compare with tirzepatide and semaglutide?

Semaglutide and tirzepatide hold regulatory approvals, have fully published phase 3 programmes and years of post-approval data, including dedicated cardiovascular outcome trials. Retatrutide now has phase 3 efficacy results of its own, some reporting larger mean weight reductions, but they are more recent, partly unpublished and not yet backed by approval or long-term real-world safety data.